340 related articles for article (PubMed ID: 14714120)
1. Fluoxetine once every third day in the treatment of major depressive disorder.
Tural U; Onder E
Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
[TBL] [Abstract][Full Text] [Related]
7. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
Mouchabac S; Ferreri M; Cabanac F; Bitton M
Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
[TBL] [Abstract][Full Text] [Related]
8. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Fava M; McGrath PJ; Sheu WP;
J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
10. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
[TBL] [Abstract][Full Text] [Related]
11. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
[TBL] [Abstract][Full Text] [Related]
12. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
[TBL] [Abstract][Full Text] [Related]
13. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
[TBL] [Abstract][Full Text] [Related]
14. Major depressive subtypes and treatment response.
Fava M; Uebelacker LA; Alpert JE; Nierenberg AA; Pava JA; Rosenbaum JF
Biol Psychiatry; 1997 Oct; 42(7):568-76. PubMed ID: 9376453
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
Lee MS; Ham BJ; Kee BS; Kim JB; Yeon BK; Oh KS; Oh BH; Lee C; Jung HY; Chee IS; Choe BM; Paik IH
Curr Med Res Opin; 2005 Sep; 21(9):1369-75. PubMed ID: 16197655
[TBL] [Abstract][Full Text] [Related]
16. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
17. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.
Jazayeri S; Tehrani-Doost M; Keshavarz SA; Hosseini M; Djazayery A; Amini H; Jalali M; Peet M
Aust N Z J Psychiatry; 2008 Mar; 42(3):192-8. PubMed ID: 18247193
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
19. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
Thase ME; Gelenberg A; Kornstein SG; Kocsis JH; Trivedi MH; Ninan P; Li T; Pedersen R; Keller M
J Psychiatr Res; 2011 Mar; 45(3):412-20. PubMed ID: 20801464
[TBL] [Abstract][Full Text] [Related]
20. Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis.
Başterzi AD; Yazici K; Buturak V; Cimen B; Yazici A; Eskandari G; Tot Acar S; Taşdelen B
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):70-5. PubMed ID: 19804808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]